SAG
MAZE

SageView Advisory Group’s Maze Therapeutics MAZE Stock Holding History

SageView Advisory Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54
Closed -$2.24K – 2578
2025
Q4 		$2.24K Buy
+54
New +$1.86K ﹤0.01% 2208

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SageView Advisory Group's MAZE Position: Q1 2026 in Review

SageView Advisory Group sold out of Maze Therapeutics (MAZE) in Q1 2026, closing a stake of 54 shares — an estimated $2.24K sold.

SageView Advisory Group first reported a position in MAZE in Q4 2025 and held it in 1 quarter. The position peaked at $2.24K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • SageView Advisory Group reported no remaining Maze Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 54 Maze Therapeutics shares in Q1 2026, an estimated $2.24K.
  • SageView Advisory Group first reported a position in Maze Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Maze Therapeutics position peaked at $2.24K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.